Ishida T - Search Results

1

Identification of clonal immunoglobulin λ light-chain gene rearrangements in AL amyloidosis using next-generation sequencing.

Kimura K, Tsukamoto S, Miyazaki K, Kawajiri-Manako C, Ishii A, Rahmutulla B, Fukuyo M, Oshima-Hasegawa N, Mitsukawa S, Takeda Y, Mimura N, Takeuchi M, Ohwada C, Iseki T, Matsusaka K, Sanada M, Yokote K, Kaneda A, Ishida T, Suzuki K, Nakaseko C, Sakaida E. Kimura K, et al. Among authors: ishida t. Exp Hematol. 2021 Sep;101-102:34-41.e4. doi: 10.1016/j.exphem.2021.08.001. Epub 2021 Aug 17. Exp Hematol. 2021. PMID: 34411686 Free article.

2

Decrease of B-type natriuretic peptide to less than 200 pg/mL predicts longer survival in cardiac immunoglobulin light chain amyloidosis.

Ishiguro K, Hayashi T, Igarashi T, Maruyama Y, Ikeda H, Ishida T, Shinomura Y. Ishiguro K, et al. Among authors: ishida t. Int J Hematol. 2015 Aug;102(2):200-4. doi: 10.1007/s12185-015-1814-0. Epub 2015 May 28. Int J Hematol. 2015. PMID: 26016720

3

Pericardial Effusion and Multiple Organ Involvement Are Independent Predictors of Mortality in Patients with Systemic Light Chain Amyloidosis.

Yuda S, Hayashi T, Yasui K, Muranaka A, Ohnishi H, Hashimoto A, Ishida T, Tsuchihashi K, Shinomura Y, Watanabe N, Miura T. Yuda S, et al. Among authors: ishida t. Intern Med. 2015;54(15):1833-40. doi: 10.2169/internalmedicine.54.3500. Epub 2015 Aug 1. Intern Med. 2015. PMID: 26234222 Free article.

4

Phase 1 study of bortezomib in combination with melphalan and dexamethasone in Japanese patients with relapsed AL amyloidosis.

Shimazaki C, Fuchida S, Suzuki K, Ishida T, Imai H, Sawamura M, Takamatsu H, Abe M, Miyamoto T, Hata H, Yamada M, Ando Y. Shimazaki C, et al. Among authors: ishida t. Int J Hematol. 2016 Jan;103(1):79-85. doi: 10.1007/s12185-015-1901-2. Epub 2015 Nov 20. Int J Hematol. 2016. PMID: 26588925 Clinical Trial.

5

[Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis during pregnancy].

Ikeda M, Oba R, Yoshiki Y, Shingaki S, Takei T, Miyazaki K, Abe Y, Tsukada N, Ishida T, Suzuki K. Ikeda M, et al. Among authors: ishida t. Rinsho Ketsueki. 2017;58(3):216-221. doi: 10.11406/rinketsu.58.216. Rinsho Ketsueki. 2017. PMID: 28381688 Japanese.

6

Feasibility of myeloablative allogeneic hematopoietic cell transplantation from unrelated donors for patients with relapsed or refractory multiple myeloma.

Shingaki S, Tsukada N, Ishida T, Suzuki K. Shingaki S, et al. Among authors: ishida t. Hematol Oncol. 2018 Feb;36(1):363-365. doi: 10.1002/hon.2470. Epub 2017 Aug 8. Hematol Oncol. 2018. PMID: 28791712 No abstract available.

7

[IgE-κ type multiple myeloma achieving complete response with novel agents].

Takei T, Ishida T, Ikeda M, Shingaki S, Miyazaki K, Yoshiki Y, Abe Y, Okazuka K, Iki S, Tsukada N, Suzuki K. Takei T, et al. Among authors: ishida t. Rinsho Ketsueki. 2017;58(11):2232-2237. doi: 10.11406/rinketsu.58.2232. Rinsho Ketsueki. 2017. PMID: 29212974 Review. Japanese.

8

The Role of Allogeneic Transplantation for Multiple Myeloma in the Era of Novel Agents: A Study from the Japanese Society of Myeloma.

Kawamura K, Tsukada N, Kanda Y, Ikeda T, Yoshida A, Ueda Y, Ishida T, Suzuki K, Murakami H. Kawamura K, et al. Among authors: ishida t. Biol Blood Marrow Transplant. 2018 Jul;24(7):1392-1398. doi: 10.1016/j.bbmt.2018.03.012. Epub 2018 Mar 16. Biol Blood Marrow Transplant. 2018. PMID: 29555314 Free article.

9

[Carfilzomib, lenalidomide, and dexamethasone therapy for refractory and relapsed multiple myeloma: a single-center study of 29 patients].

Okazuka K, Ishida T, Sato K, Miyazaki K, Yoshiki Y, Abe Y, Tsukada N, Suzuki K. Okazuka K, et al. Among authors: ishida t. Rinsho Ketsueki. 2018;59(6):698-700. doi: 10.11406/rinketsu.59.698. Rinsho Ketsueki. 2018. PMID: 29973446 Japanese.

10

Unsuppressed serum albumin levels may jeopardize the clinical relevance of the international staging system to patients with light chain myeloma.

Kasamatsu T, Ozaki S, Saitoh T, Konishi J, Sunami K, Itagaki M, Asaoku H, Cho T, Handa H, Hagiwara S, Wakayama T, Negoro A, Takezako N, Harada N, Kuroda Y, Nakaseko C, Miyake T, Inoue N, Hata H, Shimazaki C, Ohno T, Kuroda J, Murayama T, Kobayashi T, Abe M, Ishida T, Nagura E, Shimizu K. Kasamatsu T, et al. Among authors: ishida t. Hematol Oncol. 2018 Dec;36(5):792-800. doi: 10.1002/hon.2559. Epub 2018 Sep 19. Hematol Oncol. 2018. PMID: 30176173 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

4,803 results

Search Page